A quick peek into the report
Table of Contents
1.1 | Scope of the Report |
1.2 | Global Women's Health Market Segmentation |
1.3 | Key Learnings |
1.4 | Research Methodology |
1.4.1. | Data Triangulation |
1.4.2. | Key Data Points From Secondary Sources |
1.4.3. | Key Data Points From Primary Sources |
1.4.4. | Top-Down Approach (Segmental Analysis) |
1.4.5. | Bottom-Up Approach (Segmental Analysis) |
1.4.6. | Assumptions and Limitations |
1.4.7. | Data and Prediction Modelling |
2.1 | Introduction |
3.1. | Market Drivers |
3.2. | Market Challenges |
3.3. | Market Opportunities |
4.1. | Share of Key Developments & Strategies |
4.1.1. | Collaborations/ Partnerships/ Joint Ventures/ Licensing Agreements |
4.1.2. | Regulatory Approvals |
4.1.3. | Mergers and Acquisitions |
4.1.4. | Business Expansions and Product Acquisitions |
4.1.5. | Product Launches |
4.1.6. | Others |
5.1. | Regulatory Scenario |
5.2. | Patent Landscape |
6.1. | Segmentation of Global Women's Health Market, by Application |
6.2. | Reproductive Health |
6.2.1. | Infertility |
6.2.2. | Endometriosis |
6.2.3. | Poly Cystic Ovarian Syndrome (PCOS) |
6.2.4. | Contraceptives |
6.2.4.1. | Method of Contraceptive And Effectiveness |
6.2.4.2. | Types of Contraceptives |
6.3. | Post Menopausal Health |
6.3.1. | Menopause |
6.3.2. | Post Menopausal Osteoporosis |
6.4. | Urological Disorders |
6.4.1. | Urinary Incontinence |
6.4.2. | Urinary Tract Infection |
6.4.3. | Others |
7.1. | Introduction |
7.2. | Devices |
7.2.1. | Intra Uterine Devices |
7.2.2. | Vaginal Rings |
7.2.3 | Implants |
7.2.4. | Female Condoms |
7.3. | Drugs |
7.3.1. | Drugs for Treatment of Menopause |
7.3.2. | Drugs for Treatment of Menopausal Hot Flashes |
7.4. | Pharmaceutical Pipeline |
8.1. | Introduction |
8.2. | North America |
8.3. | Europe |
8.4. | Asia Pacific |
8.5. | Rest of the World |
9.1. | Abbott Laboratories |
9.1.1. | Overview |
9.1.2. | Abbott Laboratories: Product Portfolio |
9.1.3. | Financials |
9.1.3.1. | Financial Summary |
9.1.4. | Abbott Laboratories: SWOT Analysis |
9.2. | Agile THERAPEUTICS |
9.2.1. | Overview |
9.2.2. | Agile THERAPEUTICS: Product Portfolio |
9.2.3. | Financials |
9.2.3.1. | Financial Summary |
9.2.4. | Agile THERAPEUTICS: SWOT Analysis |
9.3. | Allergan plc. |
9.3.1. | Overview |
9.3.2. | Allergan plc: Product Portfolio |
9.3.3. | Financials |
9.3.4. | Allergan plc.: SWOT Analysis |
9.4. | Amgen Inc. |
9.4.1. | Overview |
9.4.2. | Amgen Inc.: Product Portfolio |
9.4.3. | Financials |
9.4.3.1 | Financial Summary |
9.4.4. | Amgen Inc.: SWOT Analysis |
9.5. | AstraZeneca PLC |
9.5.1. | Overview |
9.5.2 | AstraZeneca PLC: Product Portfolio |
9.5.3. | Financials |
9.5.3.1. | Financial Summary |
9.5.4. | AstraZeneca PLC: SWOT Analysis |
9.6. | Bayer AG |
9.6.1. | Overview |
9.6.2. | Bayer AG: Product Portfolio |
9.6.3. | Financials |
9.6.3.1. | Financial Summary |
9.6.4. | Bayer AG: SWOT Analysis |
9.7. | Eli Lilly and Company |
9.7.1. | Overview |
9.7.2. | Eli Lilly and Company: Product Portfolio |
9.7.3. | Financials |
9.7.3.1. | Financial Summary |
9.7.4. | Eli Lilly and Company: SWOT Analysis |
9.8. | Enteris BIOPHARMA, Inc |
9.8.1. | Overview |
9.8.2. | Enteris BIOPHARMA, Inc: Product Portfolio |
9.8.3. | Corporate Summary |
9.8.4. | Enteris BIOPHARMA, Inc: SWOT Analysis |
9.9. | Evestra, Inc |
9.9.1. | Overview |
9.9.2. | Evestra, Inc: Product Portfolio |
9.9.3. | Corporate Summary |
9.9.4. | Evestra, Inc: SWOT Analysis |
9.10. | FERRING PHARMACEUTICALS |
9.10.1. | Overview |
9.10.2. | FERRING PHARMACEUTICALS: Product Portfolio |
9.10.3. | Corporate Summary |
9.10.4. | FERRING PHARMACEUTICALS: SWOT Analysis |
9.11. | GEDEON RICHTER PLC |
9.11.1. | Overview |
9.11.2. | GEDEON RICHTER PLC: Product Portfolio |
9.11.3. | Financials |
9.11.3.1. | Financial Summary |
9.11.4. | GEDEON RICHTER PLC: SWOT Analysis |
9.12. | GlaxoSmithKline Plc |
9.12.1. | Overview |
9.12.2. | Glaxo: Product Portfolio |
9.12.3. | Financials |
9.12.3.1. | Financial Summary |
9.12.4. | GlaxoSmithKline Plc: SWOT Analysis |
9.13. | HRA Pharma |
9.13.1. | Overview |
9.13.2. | HRA Pharma: Product Portfolio |
9.13.3. | Corporate Summary |
9.13.4. | HRA Pharma: SWOT Analysis |
9.14. | JDS THERAPEUTICS,LLC |
9.14.1. | Overview |
9.14.2. | JDS THERAPEUTICS, LLC : Product Portfolio |
9.14.3. | Corporate Summary |
9.14.4. | JDS THERAPEUTICS, LLC: SWOT Analysis |
9.15. | NEUROCRINE BIOSCIENCES, INC. |
9.15.1. | Overview |
9.15.2. | NEUROCRINE BIOSCIENCES, INC.: Product Portfolio |
9.15.3. | Financials |
9.15.3.1. | Financial Summary |
9.15.4. | NEROCRINE BIOSCIENCES, INC.: SWOT Analysis |
9.16. | Novartis International AG |
9.16.1. | Overview |
9.16.2. | Novartis International AG: Product Portfolio |
9.16.3. | Financials |
9.16.3.1. | Financial Summary |
9.16.4. | Novartis International AG: SWOT Analysis |
9.17. | NOVEN Pharmaceuticals, Inc. |
9.17.1. | Overview |
9.17.2. | Parent Company: Hisamitsu Pharmaceutical Co., Inc.: Overview |
9.17.3. | Hisamitsu Pharmaceutical Co., Inc.: Product Portfolio |
9.17.4. | Financials |
9.17.4.1. | Financial Summary |
9.17.5. | NOVEN Pharmaceuticals, Inc.: SWOT Analysis |
9.18. | Novo Nordisk |
9.18.1. | Overview |
9.18.2. | Novo Nordisk: Product Portfolio |
9.18.3. | Financials |
9.18.3.1 | Financial Summary |
9.18.4. | Novo Nordisk: SWOT Analysis |
9.19. | Pfizer Inc. |
9.19.1. | Overview |
9.19.2. | Pfizer Inc.: Product Portfolio |
9.19.3. | Financials |
9.19.3.1. | Financial Summary |
9.19.4. | Pfizer Inc.: SWOT Analysis |
9.20. | Radius Health Inc. |
9.20.1. | Overview |
9.20.2. | Radius Health Inc.: Product Portfolio |
9.20.3. | Financials |
9.20.3.1. | Financial Summary |
9.20.4. | Radius Health Inc.: SWOT Analysis |
9.21. | Teva Pharmaceuticals Industries Limited |
9.21.1. | Overview |
9.21.2. | Teva Pharmaceuticals Industries Limited: Product Portfolio |
9.21.3. | Financials |
9.21.3.1. | Financial Summary |
9.21.4. | Teva Pharmaceuticals Industries Limited: SWOT Analysis |
9.22. | TherapeuticsMD, Inc. |
9.22.1. | Overview |
9.22.2. | TherapeuticsMD, Inc.: Product Portfolio |
9.22.3. | Financials |
9.22.3.1. | Financial Summary |
9.22.4. | TherapeuticsMD, Inc.: SWOT Analysis |
9.23. | VALEANT Pharmaceuticals International Inc. |
9.23.1. | Overview |
9.23.2. | VALEANT Pharmaceuticals International Inc.: Product Portfolio |
9.23.3. | Financials |
9.23.3.1. | Financial Summary |
9.23.4. | Valeant Pharmaceuticals International Inc.: SWOT Analysis |
9.24. | VERTICAL PHARMACEUTICALS, LLC |
9.24.1. | Overview |
9.24.2. | Parent Company: Osmotica Pharmaceuticals: Overview |
9.24.3. | VERTICAL PHARMACEUTICALS, LLC: Product Portfolio |
9.24.4. | Corporate Summary |
9.24.5. | VERTICAL PHARMACEUTICALS, LLC: SWOT Analysis |
9.25. | Veru HEALTHCARE |
9.25.1. | Overview |
9.25.2. | Veru HEALTHCARE: Product Portfolio |
9.25.3. | Financials |
9.25.3.1. | Financial Summary |
9.25.4. | Veru HEALTHCARE: SWOT Analysis |
1 | Life Expectancy of Women in Different Countries |
2 | Global Women’s Health Market (2016 & 2023) |
3 | Partnership/Collaboration/Joint Ventures/Licensing Agreements |
4 | Regulatory Approvals |
5 | Mergers & Acquisitions |
6 | Business Expansion |
7 | Product Acquisitions |
8 | Product Launches |
9 | Others |
10 | Regulatory Scenario Across The World |
11 | Patent Landscape |
12 | Sales of Drugs for the treatment of menopause ($Million) |
13 | Sales of Drugs for the Treatment of Hot Flashes ($Million) |
14 | Drugs: Approval and Patents |
15 | Pharmaceutical Pipeline |
16 | Estimated life expectancy in years in 1960 vs. 2016 |
17 | Overview: Abbott Laboratories |
18 | Overview: Agile THERAPEUTICS |
19 | Overview: Allergan plc. |
20 | Overview: Amgen Inc. |
21 | Overview: AstraZeneca PLC |
22 | Overview: Bayer AG |
23 | Overview: Eli Lilly and Company |
24 | Overview: Enteris BIOPHARMA, Inc |
25 | Overview: Evestra, Inc |
26 | Overview: FERRING PHARMACEUTICALS |
27 | Overview: GEDEON RICHTER PLC |
28 | Overview: GlaxoSmithKline Plc |
29 | Overview: HRA Pharma |
30 | Overview: JDS THERAPEUTICS, LLC |
31 | Overview: NEUROCRINE BIOSCIENCES, INC. |
32 | Overview: Novartis AG |
33 | Overview: NOVEN Pharmaceuticals, Inc |
34 | Overview: Hisamitsu Pharmaceutical Co., |
35 | Overview: NOVO NORDISK |
36 | Overview: Pfizer Inc. |
37 | Overview: Radius Health Inc. |
38 | Overview: Teva Pharmaceuticals Industries Limited |
39 | Overview: TherapeuticsMD, Inc. |
40 | Overview: VALEANT Pharmaceuticals International Inc. |
41 | Overview: VERTICAL PHARMACEUTICALS, LLC |
42 | Overview: Veru HEALTHCARE |
1 | Some of The Issues Related to Women’s Health |
2 | Market Dynamics: Drivers & Restraints |
3 | Global Women’s Health Market Value, 2016-2023 ($Million) |
4 | Global Women's Health Market, 2016-2023 ($Million), by Application |
5 | Global Women’s Health Market, by Application, 2016 |
6 | Global Women’s Health Market, by Application, 2023 |
7 | Global Women’s Contraceptive Market by Type, 2016 |
8 | Global Women’s Contraceptive Market Type, 2023 |
9 | Global Conventional Women’s Contraceptive Market, by Product Type, 2016 |
10 | Global Conventional Women’s Contraceptive Market, by Product Type, 2023 |
11 | Global Women's Health Market Value by Geography, 2016 & 2023 ($Million) |
12 | Global Women's Health Market, by Geography, 2016 |
13 | Global Women's Health Market, by Geography, 2023 |
14 | Global Women’s Health Market Segmentation |
15 | Research Methodology |
16 | Data Triangulation |
17 | Top-Down Approach (Segmental Analysis) |
18 | Bottom-Up Approach (Segmental Analysis) |
19 | Assumptions and Limitations |
20 | Human Female Reproductive System |
21 | Market Dynamics: Drivers, Challenges & Opportunities |
22 | Share of Key Developments & Strategies |
23 | Market Share of Various Companies, 2016 |
24 | Global Women’s Health Market, by Application |
25 | Global Women’s Health Market, by Application, 2016-2023 ($Million) |
26 | Reproductive Health of Women |
27 | Global Women’s Contraception Market by Type, 2016-2023 ($Million) |
28 | Global Conventional Contraceptive Market, by Geography 2016-2023 ($Million) |
29 | Global Emergency Contraceptive Market, by Geography 2016-2023 ($Million) |
30 | Method of Contraception And Effectiveness |
31 | Types of Intra Uterine Devices |
32 | Global Conventional Contraceptives Market by Product Type, 2016-2023 ($Million) |
33 | Global Oral Contraceptive Market, 2016-2023 ($Million) |
34 | Global Oral Contraceptive Market, by Product Type, 2016-2023 ($Million) |
35 | Global Oral Contraceptive Market, by Geography, 2016-2023 ($Million) |
36 | Global IUDs Market, by Geography, 2016-2023 ($Million) |
37 | Global Female Condom, Diaphragm & Sponge Market, by Geography, 2016-2023 ($Million) |
38 | Global Contraceptive Implants Market, by Geography, 2016-2023 ($Million) |
39 | Global Vaginal Rings Market, by Geography, 2016-2023 ($Million) |
40 | Global Others Contraceptive Market, by Geography, 2016-2023 ($Million) |
41 | Drugs for Treatment of Post Menopausal Health |
42 | Number of women with menopause- 1998 (estimated) Vs 2025 (Projected) |
43 | Global Menopausal Hot Flash Treatment Market, by Drug Class 2016-2023 ($Million) |
44 | Global Menopausal Hot Flash Treatment Market, by Geography 2016-2023 ($Million) |
45 | The U.S. Menopausal Hot Flash Market, 2016-2023 ($Million) |
46 | Canada Menopausal Hot Flash Market, 2016-2023 ($Million) |
47 | The U.K. Menopausal Hot Flash Market, 2016-2023 ($Million) |
48 | Germany Menopausal Hot Flash Market, 2016-2023 ($Million) |
49 | France Menopausal Hot Flash Market, 2016-2023 ($Million) |
50 | Rest of Europe Menopausal Hot Flash Market, 2016-2023 ($Million) |
51 | Australia Menopausal Hot Flash Market, 2016-2023 ($Million) |
52 | Japan Menopausal Hot Flash Market, 2016-2023 ($Million) |
53 | India Menopausal Hot Flash Market, 2016-2023 ($Million) |
54 | China Menopausal Hot Flash Market, 2016-2023 ($Million) |
55 | Rest of Asia Pacific Menopausal Hot Flash Market, 2016-2023 ($Million) |
56 | Latin America Menopausal Hot Flash Market, 2016-2023 ($Million) |
57 | MENA Region Menopausal Hot Flash Market, 2016-2023 ($Million) |
58 | Treatment of Post Menopausal Osteoporosis |
59 | Global Post Menopausal Market, by Product 2016-2023 ($Million) |
60 | Types of Urological Disorders |
61 | Population Affected by Urinary Incontinence |
62 | Ratio of occurrence of UTI in women vs men |
63 | Global Urinary Tract Infection Market, 2016-2023 ($Million) |
64 | Global Urinary Tract Infection Market, by Geography 2016-2023 ($Million) |
65 | The U.S. UTI Market, 2016-2023 ($Million) |
66 | Canada UTI Market, 2016-2023 ($Million) |
67 | The U.K. UTI Market, 2016-2023 ($Million) |
68 | Germany UTI Market, 2016-2023 ($Million) |
69 | France UTI Market, 2016-2023 ($Million) |
70 | Italy UTI Market, 2016-2023 ($Million) |
71 | Spain UTI Market, 2016-2023 ($Million) |
72 | Rest of Europe UTI Market, 2016-2023 ($Million) |
73 | Australia UTI Market, 2016-2023 ($Million) |
74 | Japan UTI Market, 2016-2023 ($Million) |
75 | India UTI Market, 2016-2023 ($Million) |
76 | China UTI Market, 2016-2023 ($Million) |
77 | Rest of Asia Pacific UTI Market, 2016-2023 ($Million) |
78 | Brazil UTI Market, 2016-2023 ($Million) |
79 | Mexico UTI Market, 2016-2023 ($Million) |
80 | Rest of Latin America UTI Market, 2016-2023 ($Million) |
81 | Classification of Products |
82 | Intra Uterine Devices (IUD) |
83 | Types of IUDs |
84 | IUDs By Year of FDA Approval |
85 | Drugs used for the treatment of female health |
86 | Global Women's Health Market, By Region |
87 | Global Women’s Health Market, by Region 2016-2023 ($Million) |
88 | Women’s Health Market, North America 2017-2023 ($Million) |
89 | North American Women’s Health Market, by Application 2017-2023 ($Million) |
90 | The U.S. Women’s Health Market, 2016-2023 ($Million) |
91 | The U.S. Women’s Health Market, by Application 2016-2023 ($Million) |
92 | The Canada Women’s Health Market, 2016-2023 ($Million) |
93 | Canada Women’s Health Market, by Application 2016-2023 ($Million) |
94 | Women’s Health Market Europe, 2017-2023 ($Million) |
95 | European Women’s Health Market, by Application 2017-2023 ($Million) |
96 | The U.K. Women’s Health Market, 2016-2023 ($Million) |
97 | The U.K. Women’s Health Market, by Application 2016-2023 ($Million) |
98 | Germany Women’s Health Market, 2016-2023 ($Million) |
99 | Germany Women’s Health Market, by Application 2016-2023 ($Million) |
100 | France Women’s Health Market, 2016-2023 ($Million) |
101 | France Women’s Health Market, by Application 2016-2023 ($Million) |
102 | Italy Women’s Health Market, 2016-2023 ($Million) |
103 | Italy Women’s Health Market, by Application 2016-2023 ($Million) |
104 | Spain Women’s Health Market, 2016-2023 ($Million) |
105 | Spain Women’s Health Market, 2016-2023 ($Million) |
106 | Rest of Europe Women’s Health Market, 2016-2023 ($Million) |
107 | Rest of Europe Women’s Health Market, 2016-2023 ($Million) |
108 | Women’s Health Market, Asia Pacific 2016-2023 ($Million) |
109 | Asia Pacific Women’s Health Market, by Application 2017-2023 ($Million) |
110 | Japan Women’s Health Market, 2016-2023 ($Million) |
111 | Japan Women’s Health Market, by Application 2016-2023 ($Million) |
112 | Australia Women’s Health Market, 2016-2023 ($Million) |
113 | Australia Women’s Health Market, by Application 2016-2023 ($Million) |
114 | China Women’s Health Market, 2016-2023 ($Million) |
115 | China Women’s Health Market, by Application 2016-2023 ($Million) |
116 | India Women’s Health Market, 2016-2023 ($Million) |
117 | India Women’s Health Market, by Application 2016-2023 ($Million) |
118 | Rest of Asia Pacific Women’s Health Market, 2016-2023 ($Million) |
119 | Rest of Asia Pacific Women’s Health Market, by Application 2016-2023 ($Million) |
120 | Women’s Health Market, Latin America 2017-2023 ($Million) |
121 | Latin American Women’s Health Market, by Application 2017-2023 ($Million) |
122 | Mexico Women’s Health Market, 2016-2023 ($Million) |
123 | Mexico Women’s Health Market, 2016-2023 ($Million) |
124 | Brazil Women’s Health Market, 2016-2023 ($Million) |
125 | Brazil Women’s Health Market, by Application 2016-2023 ($Million) |
126 | Rest of Latin America Women’s Health Market, 2016-2023 ($Million) |
127 | Rest of Latin America Women’s Health Market, by Application 2016-2023 ($Million) |
128 | Women’s Health Market, Rest of the World 2017-2023 ($Million) |
129 | Rest of the World Women’s Health Market, by Application 2017-2023 ($Million) |
130 | Abbott Laboratories: Product Portfolio |
131 | Abbott Laboratories : Overall Financials (2014-2016) |
132 | Abbott Laboratories: Net Revenue By Business Segments (2014-2016) |
133 | Abbott Laboratories: Net Revenue By Geography (2014-2016) |
134 | Abbott Laboratories: SWOT Analysis |
135 | Agile THERAPEUTICS: Product Portfolio |
136 | Agile THERAPEUTICS: Overall Financials (2014-2016) |
137 | Agile THERAPEUTICS: Research and Development Expenses (2014-2016) |
138 | Agile THERAPEUTICS: SWOT Analysis |
139 | Allergan plc: Product portfolio |
140 | Allergan plc: Overall Financials (2014-2016) |
141 | Allergan plc: Net Revenue by Business Sub-Segment of The U.S. Specialized Therapeutics (2015-2016) |
142 | Allergan plc: Net Revenue by Business Segment (2014) |
143 | Allergan plc: Net Revenue By Business Segment (2015-2016) |
144 | Allergan plc: SWOT Analysis |
145 | Amgen Inc.: Product Portfolio |
146 | Amgen Inc.: Overall Financials (2014-2016) |
147 | Amgen: Net Revenue by Geography (2014-2016) |
148 | Amgen Inc: SWOT Analysis |
149 | AstraZeneca PLC: Product Portfolio |
150 | AstraZeneca PLC: Net Revenue By Business Segments (2014-2016) |
151 | AstraZeneca plc: Revenue By Different Geographies (2014-2016) |
152 | AstraZeneca PLC: SWOT Analysis |
153 | Bayer AG: Product Portfolio |
154 | Bayer AG : Overall Financials, 2014-2016 |
155 | Bayer AG: Net Revenue by Business Segments (2014-2016) |
156 | Bayer AG: Net Revenue By Geography (2014-2016) |
157 | Bayer AG: SWOT Analysis |
158 | Eli Lilly and Company: Product Portfolio |
159 | Eli Lilly and Company: Overall Financials (2014-2016) |
160 | Eli Lilly and Company: Net Sales By Business Segment (2014-2016) |
161 | Eli Lilly and Company: Net Sales By Geography (2014-2016) |
162 | Eli Lilly and Company: SWOT Analysis |
163 | Enteris BIOPHARMA, Inc: Product Portfolio |
164 | Enteris BIOPHARMA ,Inc: SWOT Analysis |
165 | Evestra, Inc: Product portfolio |
166 | Evestra, Inc: SWOT Analysis |
167 | FERRING PHARMACEUTICALS: Product Portfolio |
168 | FERRING PHARMACEUTICALS: SWOT Analysis |
169 | GEDEON RICHTER PLC: Product Portfolio |
170 | GEDEON RICHTER PLC,: Overall Financials(2014-2016) |
171 | GEDEON RICHTER PLC: Net Revenue by Business Segments (2014-2016) |
172 | GEDEON RICHTER PLC: Net Revenue By Geography (2016) |
173 | GEDEON RICHTER PLC: Net Revenue By Geography (2014-2015) |
174 | ON RICHTER PLC: Net Revenue By Geography (2014-2016) |
175 | GEDEON RICHTER PLC: NET REVENUE WOMEN’S HEALTHCARE(2014-2016) |
176 | GEDEON RICHTER PLC: SWOT Analysis |
177 | GlaxoSmithKline Plc: Product Portfolio |
178 | GlaxoSmithKline Plc.: Overall Financials (2013-2016) |
179 | GlaxoSmithKline: Net Revenue By Business Segments (2014-2016) |
180 | GlaxoSmithKline: Net Revenue By Geography |
181 | GlaxoSmithKline Plc: Net Revenue by Geography (2016) |
182 | GlaxoSmithKline Plc: SWOT Analysis |
183 | HERA Pharma: Product portfolio |
184 | HERA Pharm :SWOT Analysis |
185 | JDS THERAPEUTICS, LLC: Product Portfolio |
186 | JDS THERAPEUTICS ,LLC :SWOT Analysis |
187 | NEUROCRINE BIOSCIENCES, INC.: Product Portfolio |
188 | NEUROCRINE BIOSCIENCES, INC: Overall Financials (2014-2016) |
189 | NEUROCRINE BIOSCIENCES, INC.: R&D Expenses by Segment (2014-2016) |
190 | NEUROCRINE BIOSCIENCES, INC.: R&D Expenses of External Development by Product(2014-2016) |
191 | NEUROCRINE BIOSCIENCES, INC: SWOT Analysis |
192 | Novartis AG: Product Portfolio |
193 | Novartis: Overall Financials (2014-2016) |
194 | Novartis: Net Revenue by Business Segments (2013-2014) |
195 | Novartis: Net Revenue by Business Segments (2015-2016) |
196 | Novartis: Net Revenue by Geography (2016) |
197 | Novartis: Net Revenue by Geography (2014-2015) |
198 | Figure: Novartis AG: SWOT Analysis |
199 | NOVEN Pharmaceuticals, Inc: Product Portfolio |
200 | Hisamitsu Pharmaceuticals Co. Inc.: Overall Financials |
201 | Hisamitsu pharmaceuticals Co. Inc.: Net sales by Business segment (2014-2016) |
202 | NOVEN Pharmaceuticals, Inc: Overall Financials (2014-2016) |
203 | Hisamitsu pharmaceuticals Co. Inc.: Net sales by Geographical Segment (2014-2016) |
204 | NOVEN Pharmaceuticals: SWOT Analysis |
205 | NOVO NORDISK: Product Portfolio |
206 | Novo Nordisk: Overall Financials, 2014-2016 |
207 | Novo Nordisk: Net Revenue By Business Segment (2014-2016) |
208 | Novo Nordisk; Net Revenue by Geography (2014-2016) |
209 | Novo Nordisk: SWOT Analysis |
210 | Pfizer Inc.: Product Portfolio |
211 | Pfizer Inc.: Overall Financials(2014-2016) |
212 | Pfizer: Net Revenue by Geography (2014-2016) |
213 | Pfizer: Net Revenue by Business Segments (2014-2016) |
214 | Pfizer Inc.: SWOT Analysis |
215 | Radius Health Inc.: Product Portfolio |
216 | Radius Health Inc: Overall Financials (2014-2016) |
217 | Radius Health Inc.: Research and Development Expenses BY Product (2014-2016) |
218 | Radius Health Inc.: SWOT Analysis |
219 | Teva Pharmaceutical Industries Limited: Product Portfolio |
220 | Teva Pharmaceuticals Industries Limited: Overall Financials (2014-2016) |
221 | Teva Pharmaceutical Industries: Net Revenue by Geography (2014-2016) |
222 | Teva Pharmaceutical Industries Limited: Net Revenue by Sub-Segments (2014-2016) |
223 | Teva Pharmaceutical Industries: Net Revenue by Business Segment (2014-2016) |
224 | Teva Pharmaceutical Industries Ltd.: SWOT Analysis |
225 | TherapeuticsMD, Inc.: Product Portfolio |
226 | TherapeuticsMD: Overall Financials (2014-2016) |
227 | TherapeuticsMD, Inc. : SWOT Analysis |
228 | VALEANT Pharmaceuticals International Inc.: Product Portfolio |
229 | VALEANT Pharmaceuticals International Inc: Overall Financials (2014-2016) |
230 | VALEANT Pharmaceuticals International Inc: Net Revenue by Business Segment (2014-2016) |
231 | VALEANT Pharmaceuticals International Inc: Net Revenue by Region (2014-2016) |
232 | Valeant Pharmaceuticals : SWOT Analysis |
233 | VERTICAL PHARMACEUTICALS, LLC: Product Portfolio |
234 | VERTICAL PHARMACEUTICALS, LLC: SWOT Analysis |
235 | Veru HEALTHCARE: Product Portfolio |
236 | Veru HEALTHCARE: Overall Financials (2014-2016) |
237 | Veru HELTHCARE:Net revenue by Geography (2014) |
238 | Veru HEALTHCARE: NET REVENUE BY GEOGRAPHY 2015-2016) |
239 | Veru HEALTHCARE: SWOT Analysis |
Report Description
The world population is constantly increasing & was estimated to be approximately 7.5 billion in April 2017. Women accounted for 49.6% of the total world population. They form an important part of the society and hence, the concerns regarding women’s health are pivotal for the overall well-being of the society. Women have higher life expectancy than men but a longer life does not ensure a healthy life.
Women health has long been a neglected issue, worldwide. Women undergo several biological, physical & psychological changes during their lifetime. These reoccurring changes, along with ageing, consequently lead to several health issues and related problems. The world population is ageing faster and women accounted for 54% of the population belonging to the age group of 60 years or over, in 2015. This percentage is expected to increase in the coming years. The different health issues that women face include infertility, hormonal changes, postmenopausal disorders and urinary infections, among others. The use of contraceptives by women is another issue that needs to be addressed. The market analysis includes an in-depth examination of the key ecosystem players and the key strategies & developments taking place in this market. Additionally, it includes the market dynamics (market drivers, opportunities and challenges) and industry analysis.
The purpose of the study is to gain a holistic view of the women’s health market in terms of the various factors influencing it, such as recent trends, technological advancements, and regulatory aspects of the market. The scope of this report is centred upon conducting a detailed study of the solutions allied with the women’s health market. The market has been segmented into ‘application’, ‘product’ and ‘geographical regions’. The report presents the reader with an opportunity to unlock the comprehensive insights with respect to the market and helps in forming well informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.
This research report aims at answering various aspects of the global women’s health market with the help of the key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The study considers the growth-share matrix model for a comprehensive study of the global women’s health market and assesses the factors governing the same.
The key players which have been significantly contributing to the Women’s health market are Neurocrine Biosciences, Gedeon Richter Plc, Ferring Pharmaceuticals, enteris BIOPHARMA, Bayer Healthcare, F. Hoffmann-La Roche AG, Pfizer Inc., Novo Nordisk, Allergan, Plc, Radius Health Inc., Agile THERAPEUTICS, Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals, Vertical Pharmaceuticals, and Veru HEALTHCARE, among others.
Key Questions Answered in this Report
The answers to the following key questions can be derived from this report:
• What are the major market drivers, challenges and opportunities in the global women’s health market?
• How did the women’s health market evolve in the past and what is its scope in the future?
• What is the market share of the leading segments and sub-segments of the global women’s health market in 2016 and 2023?
• How will each segment of the global women’s health market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2023?
• What are the influencing factors that may affect the market share of the key players?
• How will the industry evolve during the forecast period 2016- 2023?
• What are the key developmental strategies that are being implemented by the key players to stand out in this market?
• How the market has been segmented on the basis of application?
• What are the treatment options for postmenopausal symptoms?
• What is the estimated value for menopausal hot flash market?
• What is the value of different types of contraceptives in the market?
• What will be the value of hormonal contraceptives segment by 2023?
• Which geographical location will contribute to the highest sales of the products?
Market Overview
The concern regarding women’s health is pivotal for the overall well-being of the society. Yet, it is an issue that has always been neglected due to several sociocultural factors prevailing in the society. The advent of the 21st century witnessed a sharp rise in the level of awareness among people regarding women’s health, the focus is now on better education and accessibility of services in different countries. As estimated in April 2017, the total world population accounted for approximately 7.5 billion out of which women accounted for 49.6%. Though it has been observed that women live longer than men, a longer life does not indicate a healthy life. Women undergo a lot of hormonal, emotional and physiological changes during their lifetime. The focus is now on providing better education and accessibility to services in different countries across the globe.
The purpose of the study is to gain a holistic view of the women’s health market in the terms of various factors influencing it, such as recent trends, technological advancements, and the regulatory aspects of the market. The scope of this report is centred upon conducting a detailed study of the solutions allied with the women’s health market. The market has been segmented into ‘Application’, ‘product’, and ‘geographical regions’.
The global women’s health market was estimated at $30.88 billion in 2016 and is estimated to grow over $42.12 billion by 2023. The rising geriatric population among women leading to higher incidence rate of menopause and related diseases is the major factor driving the growth of the market. With women becoming more career oriented and marriages being delayed, the infertility rates have been increasing. Other factors affecting women health include stress and changing lifestyle.
The global women’s health market can be segmented on the basis of applications, such as reproductive, menopausal, urological & others. The major contributor to the market growth, in 2016, was the contraceptives. The contraceptive market was estimated at $15.97 billion in 2016. Based on the product, the market has been segmented into drugs & devices.
North America was the major revenue contributing region, by geography, because of the rising population of elderly women and higher life expectancy leading to the increased prevalence of menopausal conditions and osteoporosis. It was estimated at $13.64 billion in 2016 & is expected to reach $17.36 billion in 2023. The region also exhibits a higher prevalence of obesity which leads to the higher prevalence of infertility. It has been observed that more menopausal symptoms were reported among the American women. The highest CAGR is expected to be of Latin America with a value of 7.1%, during the forecast period 2017-2023.
The emerging opportunities for the women’s health market are the treatment options for various conditions like PCOS, reproductive health diseases, and endometriosis, among others. The market has not witnessed innovative and breakthrough therapies in the recent years. The rising emphasis on the wellbeing of women, the increased awareness about contraceptives and pharmaceuticals and use of natural hormonal preparations are other factors which will guide the growth of the market.
The report provides in-depth SWOT analysis of different key players of the market, supported by a financial summary of each of the players. Some of the key players are Neurocrine Biosciences, Gedeon Richter Plc, Ferring Pharmaceuticals, enteris BIOPHARMA, Bayer Healthcare, F. Hoffmann-La Roche AG, Pfizer Inc., Novo Nordisk, Allergan, Plc, Radius Health Inc., Agile THERAPEUTICS, Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals, Vertical Pharmaceuticals, and Veru HEALTHCARE.
Global Women's Health Product (Drugs & Devices) Market - Analysis and Forecast (2017-2023)
(Focus on Contraceptives, Menopausal Hot Flash Drug Market, Country Analysis, and Competitive Landscape)